3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
24
Breast
5
Gynecologic
4
Gastrointestinal
4
CNS
3
Thoracic
2
Lymphoid
2
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Conditions
Multiple Myeloma
336
Neoplasms, Plasma Cell
99
Myelodysplastic Syndromes
89
Leukemia, Lymphocytic, Chronic, B-Cell
89
Precursor Cell Lymphoblastic Leukemia-Lymphoma
88
Hodgkin Disease
85
Lymphoma, Non-Hodgkin
84
Leukemia, Myeloid, Acute
83
Lymphoma, Follicular
71
Leukemia
71
Lymphoma
69
Lymphoma, Mantle-Cell
67
Lymphoma, B-Cell, Marginal Zone
63
Burkitt Lymphoma
63
Lymphoma, Large B-Cell, Diffuse
59
Lymphoma, Large-Cell, Immunoblastic
55
Recurrence
52
Myeloproliferative Disorders
49
Leukemia, Myeloid, Chronic-Phase
48
Primary Myelofibrosis
46
Leukemia, Myeloid, Accelerated Phase
43
Leukemia, Myelomonocytic, Chronic
41
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
38
Dendritic Cell Sarcoma, Interdigitating
37
Congenital Abnormalities
35
Blast Crisis
34
Waldenstrom Macroglobulinemia
27
Myelodysplastic-Myeloproliferative Diseases
25
Lymphoma, T-Cell, Cutaneous
25
Immunoglobulin Light-chain Amyloidosis
25
Interventions
Specimen Handling
4
Zoledronic Acid
3
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
dabrafenib
2
copanlisib
2
abiraterone
2
Sunitinib
2
Sorafenib
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Immunoglobulin G
2
HhAntag691
2
Fluorouracil
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Clodronic Acid
2
Bevacizumab
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Cyclophosphamide
×
Plasma cell
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled